8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Jan 30, 2026·SEC
Material company update
Dec 19, 2025·SEC
Spero Therapeutics, Inc.(SPRO)Earnings, Financials & Key Ratios
SPRO•NASDAQ
$2.53
$142M mkt cap·Price updated May 6, 2026
AboutSpero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$48M-53.8%
- EBITDA-$73M-435.8%
- Net Income-$69M-400.6%
- EPS (Diluted)-1.27-395.3%
- Gross Margin-101.67%-301.6%
- EBITDA Margin-152.9%-826.3%
- Operating Margin-152.91%-838.7%
- Net Margin-142.91%-750.3%
- ROE-89.62%-459.2%
- ROIC-327.16%-197.3%
- Debt/Equity0.09+79.7%
SPRO Key Insights
Spero Therapeutics, Inc. (SPRO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 21.5%
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SPRO Price & Volume
Spero Therapeutics, Inc. (SPRO) stock price & volume — 10-year historical chart
Loading chart...
SPRO Growth Metrics
Spero Therapeutics, Inc. (SPRO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years21.46%
3 Years150.01%
TTM-64.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1347.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1243.29%
Return on Capital
10 Years-305.52%
5 Years-43.89%
3 Years-28.9%
Last Year-70.98%
SPRO Recent Earnings
Spero Therapeutics, Inc. (SPRO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Mar 26, 2026EPS
$0.53
Est $0.20
+365.0%
Revenue
$41M
Est $26M
+58.8%
Q4 2025
Nov 13, 2025EPS
$0.13
Est $0.25
+48.0%
Revenue
$3M
Est $12M
-74.6%
Q3 2025
Aug 12, 2025EPS
$0.03
Est $0.38
+92.1%
Revenue
$12M
Est $11M
+7.3%
Q2 2025
May 13, 2025EPS
$0.25
Est $0.55
+54.5%
Revenue
$6M
Est $11M
-46.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 26, 2026 | $0.53vs $0.20+365.0% | $41Mvs $26M+58.8% |
| Q4 2025 | Nov 13, 2025 | $0.13vs $0.25+48.0% | $3Mvs $12M-74.6% |
| Q3 2025 | Aug 12, 2025 | $0.03vs $0.38+92.1% | $12Mvs $11M+7.3% |
| Q2 2025 | May 13, 2025 | $0.25vs $0.55+54.5% | $6Mvs $11M-46.6% |
Based on last 12 quarters of dataView full earnings history →
SPRO Peer Comparison
Spero Therapeutics, Inc. (SPRO) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 VNDA | 439.76M | 7.44 | -1.99 | 8.72% | -102.02% | -49.24% | 0.04 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 NAOV | 512.71K | 1.90 | -0.14 | 12.05% | -133.04% | -8.41% | 0.19 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 TBPH | 858.38M | 16.94 | -14.73 | 12.12% | 36.53% | 14.69% | 0.28 | |
 IDYA | 2.52B | 28.74 | -22.45 | 30.24% | -62.17% | -13.96% | 0.03 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 |
Compare SPRO vs Peers
Spero Therapeutics, Inc. (SPRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SPRO Income Statement
Spero Therapeutics, Inc. (SPRO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 335K | 1.98M | 3.97M | 18.15M | 9.33M | 3.07M | 48.58M | 103.78M | 47.98M | 35.77M |
| Revenue Growth % | - | 490.75% | 100.4% | 357.56% | -48.59% | -67.1% | 1482.38% | 113.63% | -53.77% | -64.72% |
| Cost of Goods Sold | 26.33M | 32.87M | 33.88M | 65.78M | 67M | 0 | 0 | 51.44M | 96.76M | 108.24M |
| COGS % of Revenue | 7860.6% | 1660.89% | 854.39% | 362.46% | 718.15% | - | - | 49.57% | 201.67% | - |
| Gross Profit | -26M▲ 0% | -30.89M▼ 18.8% | -29.92M▲ 3.1% | -47.63M▼ 59.2% | -57.67M▼ 21.1% | 3.07M▲ 105.3% | 48.58M▲ 1482.4% | 52.34M▲ 7.7% | -48.78M▼ 193.2% | -72.47M▲ 0% |
| Gross Margin % | -7760.6% | -1560.89% | -754.39% | -262.46% | -618.15% | 100% | 100% | 50.43% | -101.67% | -202.62% |
| Gross Profit Growth % | -236245.45% | -18.82% | 3.14% | -59.19% | -21.09% | 105.32% | 1482.38% | 7.74% | -193.2% | - |
| Operating Expenses | 33.56M | 41.73M | 42.81M | 15.59M | 21.44M | 91.04M | 90.78M | 30.86M | 24.58M | -25.66M |
| OpEx % of Revenue | 10016.72% | 2108.64% | 1079.32% | 85.9% | 229.8% | 2965.5% | 186.86% | 29.74% | 51.23% | - |
| Selling, General & Admin | 7.22M | 10.84M | 12.89M | 15.59M | 21.44M | 41.7M | 36.48M | 25.55M | 23.7M | 23.93M |
| SG&A % of Revenue | 2156.12% | 547.75% | 324.94% | 85.9% | 229.8% | 1358.34% | 75.1% | 24.62% | 49.41% | - |
| Research & Development | 26.33M | 32.87M | 33.88M | 67.88M | 69.4M | 64.53M | 47.59M | 51.44M | 96.76M | 61.71M |
| R&D % of Revenue | 7860.6% | 1660.89% | 854.39% | 374.03% | 743.87% | 2101.82% | 97.97% | 49.57% | 201.67% | - |
| Other Operating Expenses | 0 | -4.37M | 1.14M | -67.88M | -69.4M | -15.19M | 6.7M | -46.13M | -95.88M | -4M |
| Operating Income | -33.22M▲ 0% | -41.73M▼ 25.6% | -42.81M▼ 2.6% | -63.22M▼ 47.7% | -79.11M▼ 25.1% | -87.97M▼ 11.2% | -42.2M▲ 52.0% | 21.48M▲ 150.9% | -73.36M▼ 441.5% | -46.82M▲ 0% |
| Operating Margin % | -9916.72% | -2108.64% | -1079.32% | -348.36% | -847.94% | -2865.5% | -86.86% | 20.7% | -152.91% | -130.89% |
| Operating Income Growth % | -149.28% | -25.61% | -2.58% | -47.68% | -25.15% | -11.2% | 52.03% | 150.91% | -441.52% | - |
| EBITDA | -32.94M | -41.37M | -42.4M | -62.47M | -78.35M | -87.33M | -41.33M | 21.85M | -73.36M | -45.32M |
| EBITDA Margin % | -9833.43% | -2090.3% | -1069.01% | -344.22% | -839.79% | -2844.46% | -85.07% | 21.05% | -152.9% | -126.71% |
| EBITDA Growth % | -147.39% | -25.58% | -2.49% | -47.34% | -25.43% | -11.45% | 52.67% | 152.86% | -435.77% | -4163.55% |
| D&A (Non-Cash Add-back) | 279K | 363K | 409K | 750K | 761K | 646K | 869K | 367K | 2K | 500 |
| EBIT | -33.22M | -41.73M | -42.81M | -63.22M | -79.11M | -87.82M | -43.81M | 26.79M | -72.48M | -45.15M |
| Net Interest Income | 0 | 0 | 841K | 1.33M | 401K | -1.59M | -1.5M | 3.94M | 4.74M | 3.16M |
| Interest Income | 0 | 303K | 1.14M | 1.33M | 401K | 346K | 1.11M | 3.94M | 4.74M | 3.16M |
| Interest Expense | 0 | 303K | 303K | 0 | 0 | 1.94M | 2.6M | 0 | 0 | 0 |
| Other Income/Expense | 580K | 1.84M | 1.14M | 2.29M | 833K | -1.78M | -4.22M | 3.92M | 4.79M | 3.27M |
| Pretax Income | -32.64M▲ 0% | -46.1M▼ 41.2% | -41.66M▲ 9.6% | -60.92M▼ 46.2% | -78.28M▼ 28.5% | -89.76M▼ 14.7% | -46.41M▲ 48.3% | 25.4M▲ 154.7% | -68.57M▼ 369.9% | -43.55M▲ 0% |
| Pretax Margin % | -9743.58% | -2329.31% | -1050.48% | -335.73% | -839.01% | -2923.65% | -95.55% | 24.48% | -142.91% | -121.75% |
| Income Tax | 0 | -363K | 0 | 0 | 0 | 0 | 0 | 2.6M | 0 | 290K |
| Effective Tax Rate % | 0% | 0.79% | 0% | 0% | 0% | 0% | 0% | 10.23% | 0% | -0.67% |
| Net Income | -25.49M▲ 0% | -46.1M▼ 80.8% | -41.66M▲ 9.6% | -60.92M▼ 46.2% | -78.28M▼ 28.5% | -89.76M▼ 14.7% | -46.41M▲ 48.3% | 22.81M▲ 149.1% | -68.57M▼ 400.6% | -43.84M▲ 0% |
| Net Margin % | -7609.25% | -2329.31% | -1050.48% | -335.73% | -839.01% | -2923.65% | -95.55% | 21.98% | -142.91% | -122.56% |
| Net Income Growth % | -151.04% | -80.84% | 9.62% | -46.24% | -28.49% | -14.66% | 48.29% | 149.13% | -400.65% | -1347.82% |
| Net Income (Continuing) | -32.64M | -39.89M | -41.66M | -60.92M | -78.28M | -89.76M | -46.41M | 22.81M | -68.57M | -43.84M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -3.81M | 355K | 355K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.86▲ 0% | -17.82▼ 361.7% | -2.60▲ 85.4% | -3.31▼ 27.3% | -3.52▼ 6.3% | -2.91▲ 17.3% | -1.23▲ 57.7% | 0.43▲ 135.0% | -1.27▼ 395.3% | -0.78▲ 0% |
| EPS Growth % | -150.65% | -361.66% | 85.41% | -27.31% | -6.34% | 17.33% | 57.73% | 134.96% | -395.35% | -1243.29% |
| EPS (Basic) | -3.86 | -17.82 | -2.60 | -3.31 | -3.52 | -2.91 | -1.23 | 0.43 | -1.27 | - |
| Diluted Shares Outstanding | 6.6M | 2.59M | 16M | 18.16M | 22.39M | 30.9M | 37.59M | 52.99M | 54.04M | 56.28M |
| Basic Shares Outstanding | 6.6M | 2.59M | 16M | 18.16M | 22.39M | 30.9M | 37.59M | 52.7M | 54.04M | 56.28M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SPRO Balance Sheet
Spero Therapeutics, Inc. (SPRO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 11.87M | 87.29M | 115.44M | 95.41M | 139.15M | 157.87M | 109.11M | 131.21M | 107.28M | 52.32M |
| Cash & Short-Term Investments | 10.31M | 87.29M | 115.44M | 82.05M | 126.91M | 146.4M | 109.11M | 76.33M | 52.89M | 48.62M |
| Cash Only | 10.31M | 87.29M | 34.08M | 29.73M | 85.21M | 112.58M | 109.11M | 76.33M | 52.89M | 48.62M |
| Short-Term Investments | 0 | 0 | 81.36M | 52.31M | 41.7M | 33.82M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 304K | 2.94M | 1.3M | 10.25M | 0 | 2.64M | 1.08M | 50.7M | 52.48M | 2.46M |
| Days Sales Outstanding | 331.22 | 542.8 | 119.46 | 206.08 | - | 314 | 8.14 | 178.3 | 399.23 | 264.47 |
| Inventory | 0 | -4.77M | -8.78M | 0 | 0 | 0 | -4.46M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 1.83M | 7.48M | 3.12M | 6.18M | 0 | 3.38M | 4.18M | 1.91M | 1.25M |
| Total Non-Current Assets | 1.9M | 6.19M | 13.56M | 10.69M | 14.31M | 13.2M | 15.7M | 51.18M | 3.27M | 1.85M |
| Property, Plant & Equipment | 1.5M | 1.16M | 2.89M | 7.15M | 8.78M | 7.56M | 5.49M | 4.16M | 3.11M | 1.69M |
| Fixed Asset Turnover | 0.22x | 1.70x | 1.37x | 2.54x | 1.06x | 0.41x | 8.85x | 24.97x | 15.41x | 14.01x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 50K | 50K | 233K | 21K | 0 | 0 | 0 | 46.59M | 0 | 0 |
| Other Non-Current Assets | 350K | 4.98M | 10.44M | 3.52M | 5.52M | 5.64M | 10.2M | 435K | 153K | 612K |
| Total Assets | 13.77M▲ 0% | 93.48M▲ 578.8% | 129.01M▲ 38.0% | 106.1M▼ 17.8% | 153.45M▲ 44.6% | 171.07M▲ 11.5% | 124.8M▼ 27.0% | 182.39M▲ 46.1% | 110.54M▼ 39.4% | 54.17M▲ 0% |
| Asset Turnover | 0.02x | 0.02x | 0.03x | 0.17x | 0.06x | 0.02x | 0.39x | 0.57x | 0.43x | 0.47x |
| Asset Growth % | 91.92% | 578.76% | 38.01% | -17.75% | 44.62% | 11.48% | -27.05% | 46.14% | -39.39% | -211.53% |
| Total Current Liabilities | 6.92M | 8.16M | 12.32M | 26.66M | 14.34M | 18.67M | 21.65M | 37.15M | 49.07M | 13.65M |
| Accounts Payable | 1.14M | 3.47M | 3.6M | 4.15M | 1.16M | 1.1M | 617K | 1.38M | 7.31M | 1.4M |
| Days Payables Outstanding | 15.79 | 38.53 | 38.81 | 23.01 | 6.29 | - | - | 9.78 | 27.56 | 9.48 |
| Short-Term Debt | 0 | 0 | 0 | 928K | 0 | 0 | 0 | 1.72M | 0 | 1.9M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 1.86M | 10.37M | 27.11M | 22.12M | 41.74M |
| Other Current Liabilities | 3.7M | 3.32M | 6.34M | 18.96M | 0 | 0 | 0 | 3.22M | 0 | 7.97M |
| Current Ratio | 1.72x | 10.70x | 9.37x | 3.58x | 9.70x | 8.46x | 5.04x | 3.53x | 2.19x | 2.19x |
| Quick Ratio | 1.72x | 11.29x | 10.08x | 3.58x | 9.70x | 8.46x | 5.25x | 3.53x | 2.19x | 2.19x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 254.99 |
| Total Non-Current Liabilities | 493K | 365K | 833K | 4.87M | 7.07M | 64.11M | 27.22M | 38.34M | 15.35M | 14.03M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.45M |
| Capital Lease Obligations | 0 | 0 | 0 | 4.62M | 6.89M | 5.97M | 4.96M | 3.83M | 2.55M | 6.49M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 493K | 365K | 833K | 249K | 177K | 49.35M | 96K | 87K | 576K | 25.73M |
| Total Liabilities | 7.41M | 8.52M | 13.15M | 31.53M | 21.41M | 82.78M | 48.87M | 75.5M | 64.42M | 27.68M |
| Total Debt | 0 | 0 | 0 | 5.54M | 7.84M | 7.33M | 6.65M | 5.54M | 4.3M | 3.35M |
| Net Debt | -10.31M | -87.29M | -34.08M | -24.18M | -77.37M | -105.25M | -102.46M | -70.79M | -48.59M | -45.27M |
| Debt / Equity | - | - | - | 0.07x | 0.06x | 0.08x | 0.09x | 0.05x | 0.09x | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - | - | 0.25x | - | -0.07x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -3.24x | - | 1.00x |
| Interest Coverage | - | -137.72x | -141.27x | - | - | -45.35x | -16.20x | - | - | - |
| Total Equity | 6.36M▲ 0% | 85.31M▲ 1241.2% | 116.21M▲ 36.2% | 74.57M▼ 35.8% | 132.04M▲ 77.1% | 88.29M▼ 33.1% | 75.93M▼ 14.0% | 106.89M▲ 40.8% | 46.12M▼ 56.9% | 26.49M▲ 0% |
| Equity Growth % | 2575.1% | 1241.17% | 36.22% | -35.83% | 77.06% | -33.13% | -13.99% | 40.77% | -56.85% | -240.5% |
| Book Value per Share | 0.96 | 32.98 | 7.26 | 4.11 | 5.90 | 2.86 | 2.02 | 2.02 | 0.85 | 0.47 |
| Total Shareholders' Equity | 10.17M | 84.96M | 115.86M | 74.57M | 132.04M | 88.29M | 75.93M | 106.89M | 46.12M | 26.49M |
| Common Stock | 7.92M | 14K | 17K | 19K | 29K | 32K | 52K | 53K | 55K | 56K |
| Retained Earnings | -45.44M | -96.84M | -138.5M | -199.43M | -277.71M | -367.46M | -413.88M | -391.07M | -459.64M | -482.59M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -290K | -643K | -28K | 16K | -7K | -2K | 0 | 0 | 0 | 0 |
| Minority Interest | -3.81M | 355K | 355K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SPRO Cash Flow Statement
Spero Therapeutics, Inc. (SPRO) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -28.96M | -39.11M | -39.63M | -50.02M | -85.87M | -64.35M | -7.73M | -32.99M | -23.44M | -23.44M |
| Operating CF Margin % | -8644.48% | -1976.3% | -999.12% | -275.64% | -920.39% | -2095.99% | -15.91% | -31.79% | -48.87% | - |
| Operating CF Growth % | -201.41% | -35.06% | -1.31% | -26.23% | -71.68% | 25.07% | 87.99% | -326.79% | 28.95% | -159.06% |
| Net Income | -32.64M | -39.89M | -41.66M | -60.92M | -78.28M | -89.76M | -46.41M | 22.81M | -68.57M | -43.84M |
| Depreciation & Amortization | 279K | 363K | 409K | 750K | 761K | 1.12M | 1.55M | 367K | 2K | 0 |
| Stock-Based Compensation | 180K | 1.43M | 2.75M | 3.78M | 4.89M | 0 | 0 | 7.93M | 7.79M | 4.82M |
| Deferred Taxes | -580K | 83K | 0 | -808K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.59M | -1.54M | -50K | 356K | 151K | 11.43M | 15.05M | 6.28M | 1.04M | 1.69M |
| Working Capital Changes | -792K | 443K | -1.07M | 6.83M | -13.39M | 12.86M | 22.09M | -70.38M | 36.28M | 9.65M |
| Change in Receivables | -294K | -2.52M | 1.41M | -7.08M | 2.18M | 3.83M | 1.55M | -461K | -1.54M | 1.1M |
| Change in Inventory | 0 | 0 | 0 | 7.08M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -644K | 2.35M | 84K | 564K | -2.98M | -53K | -484K | 761K | 5.93M | -4.7M |
| Cash from Investing | -830K | -27K | -83.16M | 29.53M | 10.47M | 7.67M | 33.81M | 0 | 0 | 0 |
| Capital Expenditures | -830K | -27K | -2.44M | -314K | -157K | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | 247.76% | 1.36% | 61.42% | 1.73% | 1.68% | 2095.99% | - | - | - | - |
| Acquisitions | 0 | -1.18M | 83.16M | -29.84M | 0 | 39K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -27K | -83.16M | 29.84M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 34.41M | 116.11M | 69.52M | 16.14M | 130.88M | 84.05M | -29.55M | 221K | 0 | 0 |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 47.48M | -54.48M | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 221K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 8.5M | -4.75M | -977K | 350K | 1.24M | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 4.62M▲ 0% | 76.97M▲ 1564.6% | -53.26M▼ 169.2% | -4.35M▲ 91.8% | 55.48M▲ 1375.4% | 27.38M▼ 50.7% | -3.48M▼ 112.7% | -32.77M▼ 842.6% | -23.44M▲ 28.5% | -27.67M▲ 0% |
| Free Cash Flow | -29.79M▲ 0% | -39.14M▼ 31.4% | -42.06M▼ 7.5% | -50.33M▼ 19.7% | -86.03M▼ 70.9% | 0▲ 100.0% | -7.73M▲ 0% | -32.99M▼ 326.8% | -23.44M▲ 28.9% | -27.67M▲ 0% |
| FCF Margin % | -8892.24% | -1977.67% | -1060.54% | -277.37% | -922.07% | - | -15.91% | -31.79% | -48.87% | -77.37% |
| FCF Growth % | -202.73% | -31.38% | -7.47% | -19.67% | -70.92% | 100% | - | -326.79% | 28.95% | -57.81% |
| FCF per Share | -4.51 | -15.13 | -2.63 | -2.77 | -3.84 | - | -0.21 | -0.62 | -0.43 | -0.43 |
| FCF Conversion (FCF/Net Income) | 1.14x | 0.85x | 0.95x | 0.82x | 1.10x | 0.72x | 0.17x | -1.45x | 0.34x | 0.63x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.21M | 99K | 0 |
SPRO Key Ratios
Spero Therapeutics, Inc. (SPRO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -835.22% | -100.57% | -41.35% | -63.87% | -75.77% | -81.47% | -56.53% | 24.95% | -89.62% | -165.46% |
| Return on Invested Capital (ROIC) | - | - | -80.11% | -71.56% | -112.96% | -349.93% | - | 336.41% | -327.16% | -327.16% |
| Gross Margin | -7760.6% | -1560.89% | -754.39% | -262.46% | -618.15% | 100% | 100% | 50.43% | -101.67% | -202.62% |
| Net Margin | -7609.25% | -2329.31% | -1050.48% | -335.73% | -839.01% | -2923.65% | -95.55% | 21.98% | -142.91% | -122.56% |
| Debt / Equity | - | - | - | 0.07x | 0.06x | 0.08x | 0.09x | 0.05x | 0.09x | 0.09x |
| Interest Coverage | - | -137.72x | -141.27x | - | - | -45.35x | -16.20x | - | - | - |
| FCF Conversion | 1.14x | 0.85x | 0.95x | 0.82x | 1.10x | 0.72x | 0.17x | -1.45x | 0.34x | 0.63x |
| Revenue Growth | - | 490.75% | 100.4% | 357.56% | -48.59% | -67.1% | 1482.38% | 113.63% | -53.77% | -64.72% |
SPRO SEC Filings & Documents
Spero Therapeutics, Inc. (SPRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
SPRO Frequently Asked Questions
Spero Therapeutics, Inc. (SPRO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Spero Therapeutics, Inc. (SPRO) reported $35.8M in revenue for fiscal year 2024.
Spero Therapeutics, Inc. (SPRO) saw revenue decline by 53.8% over the past year.
Spero Therapeutics, Inc. (SPRO) reported a net loss of $43.8M for fiscal year 2024.
Dividend & Returns
Spero Therapeutics, Inc. (SPRO) has a return on equity (ROE) of -89.6%. Negative ROE indicates the company is unprofitable.
Spero Therapeutics, Inc. (SPRO) had negative free cash flow of $27.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More SPRO
Spero Therapeutics, Inc. (SPRO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates